Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)
尼达尼布作为二线治疗方案，用于一线治疗后进展的分化型或髓样甲状腺癌患者的安全性和有效性。欧洲癌症研究与治疗组织内分泌工作组开展的一项随机II期研究（方案1209-EnTF）。
期刊:Frontiers in Endocrinology
影响因子:4.6
doi:10.3389/fendo.2024.1403687
Leboulleux, Sophie; Kapiteijn, Ellen; Litière, Saskia; Schöffski, Patrick; Godbert, Yann; Rodien, Patrice; Jarzab, Barbara; Salvatore, Domenico; Zanetta, Sylvie; Capdevila, Jaume; Bastholt, Lars; De La Fouchardiere, Christelle; Lalami, Yassine; Bardet, Stéphane; Cornélis, Frank; Dedecjus, Marek; Links, Thera; Sents, Ward; Schlumberger, Martin; Locati, D Laura; Newbold, Katie
